Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematologic disorder characterized by complement-mediated hemolysis. C5 inhibitors (eculizumab/ravulizumab) control intravascular hemolysis but do not prevent residual extravascular hemolysis. The newly approved complement inhibitor, pegc...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Annals of hematology Ročník 101; číslo 9; s. 1971 - 1986
Hlavní autoři:	Wong, Raymond S. M., Pullon, Humphrey W. H., Amine, Ismail, Bogdanovic, Andrija, Deschatelets, Pascal, Francois, Cedric G., Ignatova, Kalina, Issaragrisil, Surapol, Niparuck, Pimjai, Numbenjapon, Tontanai, Roman, Eloy, Sathar, Jameela, Xu, Raymond, Al-Adhami, Mohammed, Tan, Lisa, Tse, Eric, Grossi, Federico V.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Berlin/Heidelberg Springer Berlin Heidelberg 01.09.2022 Springer Nature B.V
Témata:	Adult Anemia Biomarkers Blood diseases Bone marrow Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Complement Inactivating Agents - adverse effects Dehydrogenases Drug dosages FDA approval Hematology Hemoglobin Hemoglobins Hemoglobinuria, Paroxysmal - drug therapy Hemolysis Hospitals Humans Medicine Medicine & Public Health Monoclonal antibodies Oncology Original Original Article Peptides, Cyclic - adverse effects Pharmaceuticals Quality of life Hemoglobin LDH Phase I/II trials Safety Paroxysmal nocturnal hemoglobinuria (PNH) Quality of life
ISSN:	0939-5555, 1432-0584, 1432-0584
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematologic disorder characterized by complement-mediated hemolysis. C5 inhibitors (eculizumab/ravulizumab) control intravascular hemolysis but do not prevent residual extravascular hemolysis. The newly approved complement inhibitor, pegcetacoplan, inhibits C3, upstream of C5, and has the potential to improve control of complement-mediated hemolysis. The PADDOCK and PALOMINO clinical trials assessed the safety and efficacy of pegcetacoplan in complement inhibitor-naïve adults (≥ 18 years) diagnosed with PNH. Patients in PADDOCK (phase 1b open-label, pilot trial) received daily subcutaneous pegcetacoplan (cohort 1: 180 mg up to day 28 [ n = 3]; cohort 2: 270–360 mg up to day 365 [ n = 20]). PALOMINO (phase 2a, open-label trial) used the same dosing protocol as PADDOCK cohort 2 ( n = 4). Primary endpoints in both trials were mean change from baseline in hemoglobin, lactate dehydrogenase, haptoglobin, and the number and severity of treatment-emergent adverse events. Mean baseline hemoglobin levels were below the lower limit of normal in both trials (PADDOCK: 8.38 g/dL; PALOMINO: 7.73 g/dL; normal range: 11.90–18.00 g/dL), increased to within normal range by day 85, and were sustained through day 365 (PADDOCK: 12.14 g/dL; PALOMINO: 13.00 g/dL). In PADDOCK, 3 serious adverse events (SAE) led to study drug discontinuation, 1 of which was deemed likely related to pegcetacoplan and 1 SAE, not deemed related to study drug, led to death. No SAE led to discontinuation/death in PALOMINO. Pegcetacoplan was generally well tolerated and improved hematological parameters by controlling hemolysis, while also improving other clinical PNH indicators in both trials. These trials were registered at www.clinicaltrials.gov (NCT02588833 and NCT03593200).
AbstractList	Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematologic disorder characterized by complement-mediated hemolysis. C5 inhibitors (eculizumab/ravulizumab) control intravascular hemolysis but do not prevent residual extravascular hemolysis. The newly approved complement inhibitor, pegcetacoplan, inhibits C3, upstream of C5, and has the potential to improve control of complement-mediated hemolysis. The PADDOCK and PALOMINO clinical trials assessed the safety and efficacy of pegcetacoplan in complement inhibitor-naïve adults (≥ 18 years) diagnosed with PNH. Patients in PADDOCK (phase 1b open-label, pilot trial) received daily subcutaneous pegcetacoplan (cohort 1: 180 mg up to day 28 [ n = 3]; cohort 2: 270–360 mg up to day 365 [ n = 20]). PALOMINO (phase 2a, open-label trial) used the same dosing protocol as PADDOCK cohort 2 ( n = 4). Primary endpoints in both trials were mean change from baseline in hemoglobin, lactate dehydrogenase, haptoglobin, and the number and severity of treatment-emergent adverse events. Mean baseline hemoglobin levels were below the lower limit of normal in both trials (PADDOCK: 8.38 g/dL; PALOMINO: 7.73 g/dL; normal range: 11.90–18.00 g/dL), increased to within normal range by day 85, and were sustained through day 365 (PADDOCK: 12.14 g/dL; PALOMINO: 13.00 g/dL). In PADDOCK, 3 serious adverse events (SAE) led to study drug discontinuation, 1 of which was deemed likely related to pegcetacoplan and 1 SAE, not deemed related to study drug, led to death. No SAE led to discontinuation/death in PALOMINO. Pegcetacoplan was generally well tolerated and improved hematological parameters by controlling hemolysis, while also improving other clinical PNH indicators in both trials. These trials were registered at www.clinicaltrials.gov (NCT02588833 and NCT03593200). Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematologic disorder characterized by complement-mediated hemolysis. C5 inhibitors (eculizumab/ravulizumab) control intravascular hemolysis but do not prevent residual extravascular hemolysis. The newly approved complement inhibitor, pegcetacoplan, inhibits C3, upstream of C5, and has the potential to improve control of complement-mediated hemolysis. The PADDOCK and PALOMINO clinical trials assessed the safety and efficacy of pegcetacoplan in complement inhibitor-naïve adults (≥ 18 years) diagnosed with PNH. Patients in PADDOCK (phase 1b open-label, pilot trial) received daily subcutaneous pegcetacoplan (cohort 1: 180 mg up to day 28 [n = 3]; cohort 2: 270-360 mg up to day 365 [n = 20]). PALOMINO (phase 2a, open-label trial) used the same dosing protocol as PADDOCK cohort 2 (n = 4). Primary endpoints in both trials were mean change from baseline in hemoglobin, lactate dehydrogenase, haptoglobin, and the number and severity of treatment-emergent adverse events. Mean baseline hemoglobin levels were below the lower limit of normal in both trials (PADDOCK: 8.38 g/dL; PALOMINO: 7.73 g/dL; normal range: 11.90-18.00 g/dL), increased to within normal range by day 85, and were sustained through day 365 (PADDOCK: 12.14 g/dL; PALOMINO: 13.00 g/dL). In PADDOCK, 3 serious adverse events (SAE) led to study drug discontinuation, 1 of which was deemed likely related to pegcetacoplan and 1 SAE, not deemed related to study drug, led to death. No SAE led to discontinuation/death in PALOMINO. Pegcetacoplan was generally well tolerated and improved hematological parameters by controlling hemolysis, while also improving other clinical PNH indicators in both trials. These trials were registered at www.clinicaltrials.gov (NCT02588833 and NCT03593200).Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematologic disorder characterized by complement-mediated hemolysis. C5 inhibitors (eculizumab/ravulizumab) control intravascular hemolysis but do not prevent residual extravascular hemolysis. The newly approved complement inhibitor, pegcetacoplan, inhibits C3, upstream of C5, and has the potential to improve control of complement-mediated hemolysis. The PADDOCK and PALOMINO clinical trials assessed the safety and efficacy of pegcetacoplan in complement inhibitor-naïve adults (≥ 18 years) diagnosed with PNH. Patients in PADDOCK (phase 1b open-label, pilot trial) received daily subcutaneous pegcetacoplan (cohort 1: 180 mg up to day 28 [n = 3]; cohort 2: 270-360 mg up to day 365 [n = 20]). PALOMINO (phase 2a, open-label trial) used the same dosing protocol as PADDOCK cohort 2 (n = 4). Primary endpoints in both trials were mean change from baseline in hemoglobin, lactate dehydrogenase, haptoglobin, and the number and severity of treatment-emergent adverse events. Mean baseline hemoglobin levels were below the lower limit of normal in both trials (PADDOCK: 8.38 g/dL; PALOMINO: 7.73 g/dL; normal range: 11.90-18.00 g/dL), increased to within normal range by day 85, and were sustained through day 365 (PADDOCK: 12.14 g/dL; PALOMINO: 13.00 g/dL). In PADDOCK, 3 serious adverse events (SAE) led to study drug discontinuation, 1 of which was deemed likely related to pegcetacoplan and 1 SAE, not deemed related to study drug, led to death. No SAE led to discontinuation/death in PALOMINO. Pegcetacoplan was generally well tolerated and improved hematological parameters by controlling hemolysis, while also improving other clinical PNH indicators in both trials. These trials were registered at www.clinicaltrials.gov (NCT02588833 and NCT03593200). Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematologic disorder characterized by complement-mediated hemolysis. C5 inhibitors (eculizumab/ravulizumab) control intravascular hemolysis but do not prevent residual extravascular hemolysis. The newly approved complement inhibitor, pegcetacoplan, inhibits C3, upstream of C5, and has the potential to improve control of complement-mediated hemolysis. The PADDOCK and PALOMINO clinical trials assessed the safety and efficacy of pegcetacoplan in complement inhibitor-naïve adults (≥ 18 years) diagnosed with PNH. Patients in PADDOCK (phase 1b open-label, pilot trial) received daily subcutaneous pegcetacoplan (cohort 1: 180 mg up to day 28 [n = 3]; cohort 2: 270-360 mg up to day 365 [n = 20]). PALOMINO (phase 2a, open-label trial) used the same dosing protocol as PADDOCK cohort 2 (n = 4). Primary endpoints in both trials were mean change from baseline in hemoglobin, lactate dehydrogenase, haptoglobin, and the number and severity of treatment-emergent adverse events. Mean baseline hemoglobin levels were below the lower limit of normal in both trials (PADDOCK: 8.38 g/dL; PALOMINO: 7.73 g/dL; normal range: 11.90-18.00 g/dL), increased to within normal range by day 85, and were sustained through day 365 (PADDOCK: 12.14 g/dL; PALOMINO: 13.00 g/dL). In PADDOCK, 3 serious adverse events (SAE) led to study drug discontinuation, 1 of which was deemed likely related to pegcetacoplan and 1 SAE, not deemed related to study drug, led to death. No SAE led to discontinuation/death in PALOMINO. Pegcetacoplan was generally well tolerated and improved hematological parameters by controlling hemolysis, while also improving other clinical PNH indicators in both trials. These trials were registered at www.clinicaltrials.gov (NCT02588833 and NCT03593200). Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematologic disorder characterized by complement-mediated hemolysis. C5 inhibitors (eculizumab/ravulizumab) control intravascular hemolysis but do not prevent residual extravascular hemolysis. The newly approved complement inhibitor, pegcetacoplan, inhibits C3, upstream of C5, and has the potential to improve control of complement-mediated hemolysis. The PADDOCK and PALOMINO clinical trials assessed the safety and efficacy of pegcetacoplan in complement inhibitor-naïve adults (≥ 18 years) diagnosed with PNH. Patients in PADDOCK (phase 1b open-label, pilot trial) received daily subcutaneous pegcetacoplan (cohort 1: 180 mg up to day 28 [n = 3]; cohort 2: 270–360 mg up to day 365 [n = 20]). PALOMINO (phase 2a, open-label trial) used the same dosing protocol as PADDOCK cohort 2 (n = 4). Primary endpoints in both trials were mean change from baseline in hemoglobin, lactate dehydrogenase, haptoglobin, and the number and severity of treatment-emergent adverse events. Mean baseline hemoglobin levels were below the lower limit of normal in both trials (PADDOCK: 8.38 g/dL; PALOMINO: 7.73 g/dL; normal range: 11.90–18.00 g/dL), increased to within normal range by day 85, and were sustained through day 365 (PADDOCK: 12.14 g/dL; PALOMINO: 13.00 g/dL). In PADDOCK, 3 serious adverse events (SAE) led to study drug discontinuation, 1 of which was deemed likely related to pegcetacoplan and 1 SAE, not deemed related to study drug, led to death. No SAE led to discontinuation/death in PALOMINO. Pegcetacoplan was generally well tolerated and improved hematological parameters by controlling hemolysis, while also improving other clinical PNH indicators in both trials. These trials were registered at www.clinicaltrials.gov (NCT02588833 and NCT03593200).
Author	Xu, Raymond Grossi, Federico V. Wong, Raymond S. M. Francois, Cedric G. Pullon, Humphrey W. H. Tse, Eric Numbenjapon, Tontanai Niparuck, Pimjai Tan, Lisa Amine, Ismail Deschatelets, Pascal Ignatova, Kalina Roman, Eloy Bogdanovic, Andrija Sathar, Jameela Issaragrisil, Surapol Al-Adhami, Mohammed
Author_xml	– sequence: 1 givenname: Raymond S. M. surname: Wong fullname: Wong, Raymond S. M. organization: Sir Y.K. Pao Centre for Cancer and Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong – sequence: 2 givenname: Humphrey W. H. surname: Pullon fullname: Pullon, Humphrey W. H. organization: Waikato Hospital – sequence: 3 givenname: Ismail surname: Amine fullname: Amine, Ismail organization: Tokuda Hospital – sequence: 4 givenname: Andrija surname: Bogdanovic fullname: Bogdanovic, Andrija organization: Clinic of Hematology, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade – sequence: 5 givenname: Pascal surname: Deschatelets fullname: Deschatelets, Pascal organization: Apellis Pharmaceuticals – sequence: 6 givenname: Cedric G. surname: Francois fullname: Francois, Cedric G. organization: Apellis Pharmaceuticals – sequence: 7 givenname: Kalina surname: Ignatova fullname: Ignatova, Kalina organization: National Specialized Hospital for Active Treatment of Hematologic Diseases – sequence: 8 givenname: Surapol surname: Issaragrisil fullname: Issaragrisil, Surapol organization: Faculty of Medicine Siriraj Hospital – sequence: 9 givenname: Pimjai surname: Niparuck fullname: Niparuck, Pimjai organization: Ramathibodi Hospital – sequence: 10 givenname: Tontanai surname: Numbenjapon fullname: Numbenjapon, Tontanai organization: Phramongkutklao Hospital and Phramongkutklao College of Medicine – sequence: 11 givenname: Eloy surname: Roman fullname: Roman, Eloy organization: Lakes Research – sequence: 12 givenname: Jameela surname: Sathar fullname: Sathar, Jameela organization: Department of Hematology, Ampang Hospital – sequence: 13 givenname: Raymond surname: Xu fullname: Xu, Raymond organization: Apellis Pharmaceuticals – sequence: 14 givenname: Mohammed surname: Al-Adhami fullname: Al-Adhami, Mohammed organization: Apellis Pharmaceuticals – sequence: 15 givenname: Lisa surname: Tan fullname: Tan, Lisa organization: Lisa Tan Pharma Consulting Ltd – sequence: 16 givenname: Eric surname: Tse fullname: Tse, Eric organization: Department of Medicine, The University of Hong Kong – sequence: 17 givenname: Federico V. surname: Grossi fullname: Grossi, Federico V. email: federico@apellis.com organization: Apellis Pharmaceuticals
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/35869170$$D View this record in MEDLINE/PubMed
BookMark	eNp9kUtv1DAUhS1URKeFP8ACRWLDJnD9ip0NEhrxqFSJDawtj-PMuDh2sBOY4dfjZjo8uqg3tuXvHB3fc4HOQgwWoecYXmMA8SYDECFqIKQG1gKt94_QCjNarlyyM7SClrY1L-scXeR8A4CJZOQJOqdcNi0WsEL7q7BzGze5GKrYV2ta_XTTrhrt1thJmzh6Hapk8-ynXLlQhZgG7d0vfVLs7BD9IbtcDTp9s2mhRp3i_pALWQRmmlMop1ty6-PGhTk5_RQ97rXP9tndfom-fnj_Zf2pvv788Wr97ro2TLCp7k3bNLxvmBaSsa6XrNWdMLTjWHLdcL4hBHc9tbrHhlIMnGDGKEBHWyhHeoneHn3HeTPYztgwJe3VmFzJe1BRO_X_S3A7tY0_VEsFFw0pBq_uDFL8Pts8qcFlY30ZjI1zVqQppGB4QV_eQ2_i8vdCCcANBtnIQr34N9GfKKdSCiCPgEkx52R7Zdy0DLwEdF5hULf9q2P_qvSvlv7VvkjJPenJ_UERPYpygcPWpr-xH1D9BrofxX8
CitedBy_id	crossref_primary_10_1016_j_blre_2023_101041 crossref_primary_10_3390_ijms25179477 crossref_primary_10_3390_medicina61071205 crossref_primary_10_1182_blood_2023022549 crossref_primary_10_1182_bloodadvances_2022009129 crossref_primary_10_3390_biom15081179 crossref_primary_10_1016_j_jtct_2023_12_017 crossref_primary_10_1016_j_drudis_2024_104209 crossref_primary_10_1007_s40268_024_00500_7 crossref_primary_10_57264_cer_2023_0055 crossref_primary_10_3390_ijms25168591 crossref_primary_10_1371_journal_pone_0306407 crossref_primary_10_3390_medicina59091612 crossref_primary_10_1080_03007995_2024_2354533 crossref_primary_10_1002_ajh_26832 crossref_primary_10_1007_s12325_024_02827_8 crossref_primary_10_1007_s40265_025_02235_4 crossref_primary_10_3390_ijms25168698 crossref_primary_10_1016_j_medp_2025_100070 crossref_primary_10_1007_s40265_022_01809_w crossref_primary_10_3390_hematolrep15040060 crossref_primary_10_1016_j_rpth_2024_102416 crossref_primary_10_1177_20406207231216080 crossref_primary_10_31083_j_fbl2809222 crossref_primary_10_3389_fimmu_2022_1060923 crossref_primary_10_1002_jha2_714 crossref_primary_10_1093_jimmun_vkaf053
Cites_doi	10.1182/blood-2008-01-133918 10.1038/nrdp.2017.28 10.1182/blood-2018-09-876805 10.1002/cncr.10245 10.1007/bf03019668 10.1182/asheducation-2016.1.208 10.1056/NEJMoa061648 10.1177/2040620720966137 10.1016/j.molimm.2017.06.039 10.1038/nrd4657 10.1182/blood-2005-04-1717 10.1182/blood.V130.Suppl_1.3471.3471 10.1056/NEJMoa2029073 10.1007/s00277-020-04052-z 10.1111/bjh.12347 10.1182/blood.2020004959 10.1016/0092-8674(93)90250-t 10.1016/s1040-8428(99)00052-9 10.1001/jama.293.13.1653 10.1111/ejh.12021 10.1073/pnas.90.11.5272 10.1016/j.cca.2019.03.1617 10.3389/fimmu.2019.01157 10.1371/journal.pone.0032327 10.4049/jimmunol.1203200 10.3389/fimmu.2018.01749 10.1182/blood-2007-06-095646 10.3324/haematol.2013.093161 10.1182/blood-2018-09-876136 10.1046/j.1365-2141.1997.d01-1984.x 10.1056/nejm199010253231707 10.1248/bpb.b15-00703 10.1002/j.1460-2075.1994.tb06240.x 10.1586/17474086.2014.953926 10.1134/s1990750821030069 10.1038/s41409-021-01372-0 10.3324/haematol.2019.236877 10.1038/ni.1923 10.1002/ajh.24278 10.1182/blood-2008-11-189944 10.1016/S0021-9258(18)42266-1 10.1155/2015/635670 10.2147/btt.s1420 10.1016/s0885-3924(02)00529-8 10.1002/ajh.25960
ContentType	Journal Article
Copyright	The Author(s) 2022. corrected publication 2022 2022. The Author(s). The Author(s) 2022. corrected publication 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2022, corrected publication 2022
Copyright_xml	– notice: The Author(s) 2022. corrected publication 2022 – notice: 2022. The Author(s). – notice: The Author(s) 2022. corrected publication 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2022, corrected publication 2022
DBID	C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM
DOI	10.1007/s00277-022-04903-x
DatabaseName	Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Proquest Nursing & Allied Health Source Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection ProQuest Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE ProQuest One Academic Middle East (New) CrossRef
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1432-0584
EndPage	1986
ExternalDocumentID	PMC9375762 35869170 10_1007_s00277_022_04903_x
Genre	Journal Article
GrantInformation_xml	– fundername: Apellis Pharmaceuticals Inc. – fundername: ;
GroupedDBID	--- -53 -5E -5G -BR -EM -Y2 -~C -~X .86 .GJ .VR 06C 06D 0R~ 0VY 199 1N0 1SB 2.D 203 23M 28- 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5RE 5VS 67Z 6NX 78A 7RV 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AAJSJ AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACAOD ACBXY ACGFS ACHSB ACHVE ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACUDM ACULB ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFFNX AFJLC AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BKEYQ BPHCQ BSONS BVXVI C6C CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- N2Q N9A NAPCQ NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI RNS ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 WOW YLTOR Z45 Z7U Z82 Z83 Z87 Z8O Z8V Z8W Z91 ZMTXR ZOVNA ZXP ~EX ~KM AAPKM AAYXX ABBRH ABDBE ABEEZ ABFSG ACSTC ADHKG AEZWR AFDZB AFFHD AFGXO AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY CGR CUY CVF ECM EIF NPM 7XB 8FK K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-c474t-fc9665f64a7844df849ad7c3d5185a655b221df3eaf1c331052144300d3902143
IEDL.DBID	BENPR
ISICitedReferencesCount	33
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000828925100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0939-5555 1432-0584
IngestDate	Tue Nov 04 01:46:37 EST 2025 Thu Oct 02 10:11:50 EDT 2025 Tue Oct 07 06:20:36 EDT 2025 Sat Nov 01 14:15:53 EDT 2025 Sat Nov 29 05:26:19 EST 2025 Tue Nov 18 22:20:06 EST 2025 Fri Feb 21 02:45:52 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	9
Keywords	Hemoglobin LDH Phase I/II trials Safety Paroxysmal nocturnal hemoglobinuria (PNH) Quality of life
Language	English
License	2022. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c474t-fc9665f64a7844df849ad7c3d5185a655b221df3eaf1c331052144300d3902143
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
OpenAccessLink	https://link.springer.com/10.1007/s00277-022-04903-x
PMID	35869170
PQID	2701610868
PQPubID	54039
PageCount	16
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_9375762 proquest_miscellaneous_2693774162 proquest_journals_2701610868 pubmed_primary_35869170 crossref_citationtrail_10_1007_s00277_022_04903_x crossref_primary_10_1007_s00277_022_04903_x springer_journals_10_1007_s00277_022_04903_x
PublicationCentury	2000
PublicationDate	2022-09-01
PublicationDateYYYYMMDD	2022-09-01
PublicationDate_xml	– month: 09 year: 2022 text: 2022-09-01 day: 01
PublicationDecade	2020
PublicationPlace	Berlin/Heidelberg
PublicationPlace_xml	– name: Berlin/Heidelberg – name: Germany – name: Berlin
PublicationTitle	Annals of hematology
PublicationTitleAbbrev	Ann Hematol
PublicationTitleAlternate	Ann Hematol
PublicationYear	2022
Publisher	Springer Berlin Heidelberg Springer Nature B.V
Publisher_xml	– name: Springer Berlin Heidelberg – name: Springer Nature B.V
References	Lee, Sicre de Fontbrune, Wong Lee Lee, Pessoa, Gualandro, Füreder, Ptushkin, Rottinghaus, Volles, Shafner, Aguzzi, Pradhan, Schrezenmeier, Hill (CR30) 2019; 133 Nakayama, Usuki, Echizen, Ogawa, Orii (CR26) 2016; 39 Risitano, Rotoli (CR17) 2008; 2 Ullman, Horn, Abraham, VanSlyck (CR5) 1963; 11 Schrezenmeier, Muus, Socié, Szer, Urbano-Ispizua, Maciejewski, Brodsky, Bessler, Kanakura, Rosse, Khursigara, Bedrosian, Hillmen (CR19) 2014; 99 Cella, Eton, Lai, Peterman, Merkel (CR35) 2002; 24 Parker, Omine, Richards, Nishimura, Bessler, Ware, Hillmen, Luzzatto, Young, Kinoshita, Rosse, Socié (CR16) 2005; 106 Parker (CR18) 2016; 2016 Brodsky (CR31) 2020; 135 Risitano, Marotta, Ricci, Marano, Frieri, Cacace, Sica, Kulasekararaj, Calado, Scheinberg, Notaro, Peffault de Latour (CR13) 2019; 10 Ricklin, Lambris (CR37) 2013; 190 Yamashina, Ueda, Kinoshita, Takami, Ojima, Ono, Tanaka, Kondo, Orii, Okada (CR9) 1990; 323 CR33 Kazmi, Koda, Ndiaye, Visvikis-Siest, Morton, Gaunt, Galea (CR43) 2019; 494 Risitano, Notaro, Marando, Serio, Ranaldi, Seneca, Ricci, Alfinito, Camera, Gianfaldoni, Amendola, Boschetti, Di Bona, Fratellanza, Barbano, Rodeghiero, Zanella, Iori, Selleri, Luzzatto, Rotoli (CR4) 2009; 113 Cella, Lai, Chang, Peterman, Slavin (CR34) 2002; 94 Loschi, Porcher, Barraco, Terriou, Mohty, de Guibert, Mahe, Lemal, Dumas, Etienne, Jardin, Royer, Bordessoule, Rohrlich, Fornecker, Salanoubat, Maury, Cahn, Vincent, Sene, Rigaudeau, Nguyen, Lepretre, Mary, Corront, Socie, Peffault de Latour (CR40) 2016; 91 Morgan, Harris (CR36) 2015; 14 Korkama, Armstrong, Jarva, Meri (CR6) 2018; 9 DeZern, Dorr, Brodsky (CR27) 2013; 90 Froguel, Ndiaye, Bonnefond, Bouatia-Naji, Dechaume, Siest, Herbeth, Falchi, Bottolo, Guéant-Rodriguez, Lecoeur, Langlois, Labrune, Ruokonen, El Shamieh, Stathopoulou, Morandi, Maffeis, Meyre, Delanghe, Jacobson, Sjöström, Carlsson, Walley, Elliott, Jarvelin, Dedoussis, Visvikis-Siest (CR42) 2012; 7 Hillmen, Muus, Dührsen, Risitano, Schubert, Luzzatto, Schrezenmeier, Szer, Brodsky, Hill, Socié, Bessler, Rollins, Bell, Rother, Young (CR39) 2007; 110 McKinley, Richards, Munir, Griffin, Mitchell, Arnold, Riley, Copeland, Newton, Hill, Hillmen (CR23) 2017; 130 Paquette, Yoshimura, Veiseh, Kunkel, Gajewski, Rosen (CR2) 1997; 96 Naryzny, Legina (CR41) 2021; 15 Barcellini, Fattizzo (CR14) 2015; 2015 Bessler, Mason, Hillmen, Miyata, Yamada, Takeda, Luzzatto, Kinoshita (CR1) 1994; 13 Schrezenmeier, Kulasekararaj, Mitchell, Sicre de Fontbrune, Devos, Okamoto, Wells, Rottinghaus, Liu, Ortiz, Lee, Socié (CR46) 2020; 11 de Latour, Mary, Salanoubat, Terriou, Etienne, Mohty, Roth, de Guibert, Maury, Cahn, Socié (CR38) 2008; 112 Hillmen, Szer, Weitz, Röth, Höchsmann, Panse, Usuki, Griffin, Kiladjian, de Castro, Nishimori, Tan, Hamdani, Deschatelets, Francois, Grossi, Ajayi, Risitano, de la Tour (CR45) 2021; 384 Mastellos, Ricklin, Yancopoulou, Risitano, Lambris (CR15) 2014; 7 Hillmen, Young, Schubert, Brodsky, Socié, Muus, Röth, Szer, Elebute, Nakamura, Browne, Risitano, Hill, Schrezenmeier, Fu, Maciejewski, Rollins, Mojcik, Rother, Luzzatto (CR22) 2006; 355 Rother, Bell, Hillmen, Gladwin (CR20) 2005; 293 Schrezenmeier, Röth, Araten, Kanakura, Larratt, Shammo, Wilson, Shayan, Maciejewski (CR21) 2020; 99 Mehdi, Grossi, Deschatelets, Pullon, Tan, Vega, Francois (CR32) 2017; 89 Boccuni, Del Vecchio, Di Noto, Rotoli (CR10) 2000; 33 Ricklin, Hajishengallis, Yang, Lambris (CR12) 2010; 11 Hill, DeZern, Kinoshita, Brodsky (CR3) 2017; 3 Debureaux, Kulasekararaj, Cacace, Silva, Calado, Barone, Sicre de Fontbrune, Prata, Soret, Sica, Notaro, Scheinberg, Mallikarjuna, Gandhi, Large, Risitano, Peffault de Latour, Frieri (CR28) 2021 Hillmen, Bessler, Mason, Watkins, Luzzatto (CR8) 1993; 90 Kulasekararaj, Hill, Rottinghaus, Langemeijer, Wells, Gonzalez-Fernandez, Gaya, Lee, Gutierrez, Piatek, Szer, Risitano, Nakao, Bachman, Shafner, Damokosh, Ortiz, Röth, Peffault de Latour (CR29) 2019; 133 Ninomiya, Sims (CR11) 1992; 267 Nishiyama, Hanaoka (CR44) 2000; 47 Takeda, Miyata, Kawagoe, Iida, Endo, Fujita, Takahashi, Kitani, Kinoshita (CR7) 1993; 73 Hillmen, Muus, Röth, Elebute, Risitano, Schrezenmeier, Szer, Browne, Maciejewski, Schubert, Urbano-Ispizua, de Castro, Socié, Brodsky (CR25) 2013; 162 Brodsky, Peffault de Latour, Rottinghaus, Röth, Risitano, Weitz, Hillmen, Maciejewski, Szer, Lee, Kulasekararaj, Volles, Damokosh, Ortiz, Shafner, Liu, Hill, Schrezenmeier (CR24) 2021; 106 A Hill (4903_CR3) 2017; 3 H Schrezenmeier (4903_CR46) 2020; 11 W Barcellini (4903_CR14) 2015; 2015 PE Debureaux (4903_CR28) 2021 D Ricklin (4903_CR37) 2013; 190 T Nishiyama (4903_CR44) 2000; 47 DC Mastellos (4903_CR15) 2014; 7 H Nakayama (4903_CR26) 2016; 39 RL Paquette (4903_CR2) 1997; 96 P Hillmen (4903_CR45) 2021; 384 CE McKinley (4903_CR23) 2017; 130 P Hillmen (4903_CR22) 2006; 355 P Hillmen (4903_CR8) 1993; 90 ES Korkama (4903_CR6) 2018; 9 M Bessler (4903_CR1) 1994; 13 C Parker (4903_CR16) 2005; 106 RA Brodsky (4903_CR24) 2021; 106 J Takeda (4903_CR7) 1993; 73 P Hillmen (4903_CR25) 2013; 162 AM Risitano (4903_CR17) 2008; 2 CJ Parker (4903_CR18) 2016; 2016 RA Brodsky (4903_CR31) 2020; 135 AE DeZern (4903_CR27) 2013; 90 RP Rother (4903_CR20) 2005; 293 N Kazmi (4903_CR43) 2019; 494 H Schrezenmeier (4903_CR21) 2020; 99 D Mehdi (4903_CR32) 2017; 89 P Froguel (4903_CR42) 2012; 7 P Boccuni (4903_CR10) 2000; 33 M Yamashina (4903_CR9) 1990; 323 H Ninomiya (4903_CR11) 1992; 267 AM Risitano (4903_CR13) 2019; 10 4903_CR33 D Cella (4903_CR34) 2002; 94 P Hillmen (4903_CR39) 2007; 110 SN Naryzny (4903_CR41) 2021; 15 AS Ullman (4903_CR5) 1963; 11 H Schrezenmeier (4903_CR19) 2014; 99 D Cella (4903_CR35) 2002; 24 M Loschi (4903_CR40) 2016; 91 AG Kulasekararaj (4903_CR29) 2019; 133 RP de Latour (4903_CR38) 2008; 112 AM Risitano (4903_CR4) 2009; 113 D Ricklin (4903_CR12) 2010; 11 BP Morgan (4903_CR36) 2015; 14 JW Lee (4903_CR30) 2019; 133
References_xml	– volume: 112 start-page: 3099 issue: 8 year: 2008 end-page: 3106 ident: CR38 article-title: Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories publication-title: Blood doi: 10.1182/blood-2008-01-133918 – volume: 3 start-page: 17028 year: 2017 ident: CR3 article-title: Paroxysmal nocturnal haemoglobinuria publication-title: Nat Rev Dis Primers doi: 10.1038/nrdp.2017.28 – volume: 133 start-page: 540 issue: 6 year: 2019 end-page: 549 ident: CR29 article-title: Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study publication-title: Blood doi: 10.1182/blood-2018-09-876805 – volume: 94 start-page: 528 issue: 2 year: 2002 end-page: 538 ident: CR34 article-title: Fatigue in cancer patients compared with fatigue in the general United States population publication-title: Cancer doi: 10.1002/cncr.10245 – volume: 47 start-page: 881 issue: 9 year: 2000 end-page: 885 ident: CR44 article-title: Free hemoglobin concentrations in patients receiving massive blood transfusion during emergency surgery for trauma publication-title: Canadian journal of anaesthesia Journal canadien d'anesthesie doi: 10.1007/bf03019668 – volume: 2016 start-page: 208 issue: 1 year: 2016 end-page: 216 ident: CR18 article-title: Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria publication-title: Hematology doi: 10.1182/asheducation-2016.1.208 – volume: 355 start-page: 1233 issue: 12 year: 2006 end-page: 1243 ident: CR22 article-title: The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria publication-title: N Engl J Med doi: 10.1056/NEJMoa061648 – volume: 11 start-page: 2040620720966137 year: 2020 ident: CR46 article-title: One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study publication-title: Ther Adv Hematol doi: 10.1177/2040620720966137 – volume: 89 start-page: 115 year: 2017 ident: CR32 article-title: APL-2, a complement C3 inhibitor, may potentially reduce both intravascular and extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria publication-title: Mol Immunol doi: 10.1016/j.molimm.2017.06.039 – volume: 14 start-page: 857 issue: 12 year: 2015 end-page: 877 ident: CR36 article-title: Complement, a target for therapy in inflammatory and degenerative diseases publication-title: Nat Rev Drug Discov doi: 10.1038/nrd4657 – volume: 106 start-page: 3699 issue: 12 year: 2005 end-page: 3709 ident: CR16 article-title: Diagnosis and management of paroxysmal nocturnal hemoglobinuria publication-title: Blood doi: 10.1182/blood-2005-04-1717 – volume: 130 start-page: 3471 issue: Supplement 1 year: 2017 end-page: 3471 ident: CR23 article-title: Extravascular hemolysis due to C3-loading in patients with PNH treated with eculizumab: defining the clinical syndrome publication-title: Blood doi: 10.1182/blood.V130.Suppl_1.3471.3471 – ident: CR33 – volume: 384 start-page: 1028 issue: 11 year: 2021 end-page: 1037 ident: CR45 article-title: Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria publication-title: N Engl J Med doi: 10.1056/NEJMoa2029073 – volume: 99 start-page: 1505 issue: 7 year: 2020 end-page: 1514 ident: CR21 article-title: Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry publication-title: Ann Hematol doi: 10.1007/s00277-020-04052-z – volume: 162 start-page: 62 issue: 1 year: 2013 end-page: 73 ident: CR25 article-title: Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria publication-title: Br J Haematol doi: 10.1111/bjh.12347 – volume: 135 start-page: 884 issue: 12 year: 2020 end-page: 885 ident: CR31 article-title: A complementary new drug for PNH publication-title: Blood doi: 10.1182/blood.2020004959 – volume: 73 start-page: 703 issue: 4 year: 1993 end-page: 711 ident: CR7 article-title: Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria publication-title: Cell doi: 10.1016/0092-8674(93)90250-t – volume: 33 start-page: 25 issue: 1 year: 2000 end-page: 43 ident: CR10 article-title: Glycosyl phosphatidylinositol (GPI)-anchored molecules and the pathogenesis of paroxysmal nocturnal hemoglobinuria publication-title: Crit Rev Oncol Hematol doi: 10.1016/s1040-8428(99)00052-9 – volume: 293 start-page: 1653 issue: 13 year: 2005 end-page: 1662 ident: CR20 article-title: The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease publication-title: JAMA doi: 10.1001/jama.293.13.1653 – volume: 90 start-page: 16 issue: 1 year: 2013 end-page: 24 ident: CR27 article-title: Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria publication-title: Eur J Haematol doi: 10.1111/ejh.12021 – volume: 90 start-page: 5272 issue: 11 year: 1993 end-page: 5276 ident: CR8 article-title: Specific defect in N-acetylglucosamine incorporation in the biosynthesis of the glycosylphosphatidylinositol anchor in cloned cell lines from patients with paroxysmal nocturnal hemoglobinuria publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.90.11.5272 – volume: 494 start-page: 138 year: 2019 end-page: 142 ident: CR43 article-title: Genetic determinants of circulating haptoglobin concentration publication-title: Clinica chimica acta international journal of clinical chemistry doi: 10.1016/j.cca.2019.03.1617 – volume: 11 start-page: 135 issue: 2 year: 1963 end-page: 145 ident: CR5 article-title: Paroxysmal nocturnal hemoglobinuria: report of two cases with atypical features, autopsy findings, and review of pathophysiology publication-title: Henry Ford Hosp Med Bull – volume: 10 start-page: 1157 year: 2019 ident: CR13 article-title: Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT publication-title: Front Immunol doi: 10.3389/fimmu.2019.01157 – volume: 7 issue: 3 year: 2012 ident: CR42 article-title: A genome-wide association study identifies rs2000999 as a strong genetic determinant of circulating haptoglobin levels publication-title: PLoS ONE doi: 10.1371/journal.pone.0032327 – volume: 190 start-page: 3839 issue: 8 year: 2013 end-page: 3847 ident: CR37 article-title: Complement in immune and inflammatory disorders: therapeutic interventions publication-title: J Immunol doi: 10.4049/jimmunol.1203200 – volume: 9 start-page: 1749 year: 2018 ident: CR6 article-title: Spontaneous remission in paroxysmal nocturnal hemoglobinuria-return to health or transition into malignancy? publication-title: Front Immunol doi: 10.3389/fimmu.2018.01749 – volume: 110 start-page: 4123 issue: 12 year: 2007 end-page: 4128 ident: CR39 article-title: Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria publication-title: Blood doi: 10.1182/blood-2007-06-095646 – volume: 99 start-page: 922 issue: 5 year: 2014 end-page: 929 ident: CR19 article-title: Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry publication-title: Haematologica doi: 10.3324/haematol.2013.093161 – volume: 133 start-page: 530 issue: 6 year: 2019 end-page: 539 ident: CR30 article-title: Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study publication-title: Blood doi: 10.1182/blood-2018-09-876136 – volume: 96 start-page: 92 issue: 1 year: 1997 end-page: 97 ident: CR2 article-title: Clinical characteristics predict response to antithymocyte globulin in paroxysmal nocturnal haemoglobinuria publication-title: Br J Haematol doi: 10.1046/j.1365-2141.1997.d01-1984.x – volume: 323 start-page: 1184 issue: 17 year: 1990 end-page: 1189 ident: CR9 article-title: Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria publication-title: N Engl J Med doi: 10.1056/nejm199010253231707 – volume: 39 start-page: 285 issue: 2 year: 2016 end-page: 288 ident: CR26 article-title: Eculizumab dosing intervals longer than 17 days may be associated with greater risk of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria publication-title: Biol Pharm Bull doi: 10.1248/bpb.b15-00703 – volume: 13 start-page: 110 issue: 1 year: 1994 end-page: 117 ident: CR1 article-title: Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene publication-title: EMBO J doi: 10.1002/j.1460-2075.1994.tb06240.x – volume: 7 start-page: 583 issue: 5 year: 2014 end-page: 598 ident: CR15 article-title: Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape publication-title: Expert Rev Hematol doi: 10.1586/17474086.2014.953926 – volume: 15 start-page: 184 issue: 3 year: 2021 end-page: 198 ident: CR41 publication-title: Haptoglobin as a biomarker. Biomedical chemistry doi: 10.1134/s1990750821030069 – year: 2021 ident: CR28 article-title: Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study publication-title: Bone Marrow Transplant doi: 10.1038/s41409-021-01372-0 – volume: 106 start-page: 230 issue: 1 year: 2021 end-page: 237 ident: CR24 article-title: Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria publication-title: Haematologica doi: 10.3324/haematol.2019.236877 – volume: 11 start-page: 785 issue: 9 year: 2010 end-page: 797 ident: CR12 article-title: Complement: a key system for immune surveillance and homeostasis publication-title: Nat Immunol doi: 10.1038/ni.1923 – volume: 91 start-page: 366 issue: 4 year: 2016 end-page: 370 ident: CR40 article-title: Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study publication-title: Am J Hematol doi: 10.1002/ajh.24278 – volume: 113 start-page: 4094 issue: 17 year: 2009 end-page: 4100 ident: CR4 article-title: Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab publication-title: Blood doi: 10.1182/blood-2008-11-189944 – volume: 267 start-page: 13675 issue: 19 year: 1992 end-page: 13680 ident: CR11 article-title: The human complement regulatory protein CD59 binds to the alpha-chain of C8 and to the “b” domain of C9 publication-title: J Biol Chem doi: 10.1016/S0021-9258(18)42266-1 – volume: 2015 year: 2015 ident: CR14 article-title: Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia publication-title: Dis Markers doi: 10.1155/2015/635670 – volume: 2 start-page: 205 issue: 2 year: 2008 end-page: 222 ident: CR17 article-title: Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents publication-title: Biologics : targets & therapy doi: 10.2147/btt.s1420 – volume: 24 start-page: 547 issue: 6 year: 2002 end-page: 561 ident: CR35 article-title: Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales publication-title: J Pain Symptom Manage doi: 10.1016/s0885-3924(02)00529-8 – volume: 2015 year: 2015 ident: 4903_CR14 publication-title: Dis Markers doi: 10.1155/2015/635670 – volume: 99 start-page: 1505 issue: 7 year: 2020 ident: 4903_CR21 publication-title: Ann Hematol doi: 10.1007/s00277-020-04052-z – volume: 90 start-page: 16 issue: 1 year: 2013 ident: 4903_CR27 publication-title: Eur J Haematol doi: 10.1111/ejh.12021 – volume: 355 start-page: 1233 issue: 12 year: 2006 ident: 4903_CR22 publication-title: N Engl J Med doi: 10.1056/NEJMoa061648 – volume: 90 start-page: 5272 issue: 11 year: 1993 ident: 4903_CR8 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.90.11.5272 – volume: 24 start-page: 547 issue: 6 year: 2002 ident: 4903_CR35 publication-title: J Pain Symptom Manage doi: 10.1016/s0885-3924(02)00529-8 – volume: 133 start-page: 530 issue: 6 year: 2019 ident: 4903_CR30 publication-title: Blood doi: 10.1182/blood-2018-09-876136 – volume: 15 start-page: 184 issue: 3 year: 2021 ident: 4903_CR41 publication-title: Haptoglobin as a biomarker. Biomedical chemistry doi: 10.1134/s1990750821030069 – volume: 91 start-page: 366 issue: 4 year: 2016 ident: 4903_CR40 publication-title: Am J Hematol doi: 10.1002/ajh.24278 – volume: 162 start-page: 62 issue: 1 year: 2013 ident: 4903_CR25 publication-title: Br J Haematol doi: 10.1111/bjh.12347 – ident: 4903_CR33 doi: 10.1002/ajh.25960 – volume: 9 start-page: 1749 year: 2018 ident: 4903_CR6 publication-title: Front Immunol doi: 10.3389/fimmu.2018.01749 – volume: 10 start-page: 1157 year: 2019 ident: 4903_CR13 publication-title: Front Immunol doi: 10.3389/fimmu.2019.01157 – volume: 190 start-page: 3839 issue: 8 year: 2013 ident: 4903_CR37 publication-title: J Immunol doi: 10.4049/jimmunol.1203200 – volume: 89 start-page: 115 year: 2017 ident: 4903_CR32 publication-title: Mol Immunol doi: 10.1016/j.molimm.2017.06.039 – volume: 7 start-page: 583 issue: 5 year: 2014 ident: 4903_CR15 publication-title: Expert Rev Hematol doi: 10.1586/17474086.2014.953926 – volume: 267 start-page: 13675 issue: 19 year: 1992 ident: 4903_CR11 publication-title: J Biol Chem doi: 10.1016/S0021-9258(18)42266-1 – volume: 113 start-page: 4094 issue: 17 year: 2009 ident: 4903_CR4 publication-title: Blood doi: 10.1182/blood-2008-11-189944 – volume: 323 start-page: 1184 issue: 17 year: 1990 ident: 4903_CR9 publication-title: N Engl J Med doi: 10.1056/nejm199010253231707 – volume: 11 start-page: 204062072096613 year: 2020 ident: 4903_CR46 publication-title: Ther Adv Hematol doi: 10.1177/2040620720966137 – volume: 13 start-page: 110 issue: 1 year: 1994 ident: 4903_CR1 publication-title: EMBO J doi: 10.1002/j.1460-2075.1994.tb06240.x – volume: 3 start-page: 17028 year: 2017 ident: 4903_CR3 publication-title: Nat Rev Dis Primers doi: 10.1038/nrdp.2017.28 – volume: 133 start-page: 540 issue: 6 year: 2019 ident: 4903_CR29 publication-title: Blood doi: 10.1182/blood-2018-09-876805 – volume: 14 start-page: 857 issue: 12 year: 2015 ident: 4903_CR36 publication-title: Nat Rev Drug Discov doi: 10.1038/nrd4657 – volume: 384 start-page: 1028 issue: 11 year: 2021 ident: 4903_CR45 publication-title: N Engl J Med doi: 10.1056/NEJMoa2029073 – volume: 7 issue: 3 year: 2012 ident: 4903_CR42 publication-title: PLoS ONE doi: 10.1371/journal.pone.0032327 – year: 2021 ident: 4903_CR28 publication-title: Bone Marrow Transplant doi: 10.1038/s41409-021-01372-0 – volume: 110 start-page: 4123 issue: 12 year: 2007 ident: 4903_CR39 publication-title: Blood doi: 10.1182/blood-2007-06-095646 – volume: 2016 start-page: 208 issue: 1 year: 2016 ident: 4903_CR18 publication-title: Hematology doi: 10.1182/asheducation-2016.1.208 – volume: 106 start-page: 230 issue: 1 year: 2021 ident: 4903_CR24 publication-title: Haematologica doi: 10.3324/haematol.2019.236877 – volume: 39 start-page: 285 issue: 2 year: 2016 ident: 4903_CR26 publication-title: Biol Pharm Bull doi: 10.1248/bpb.b15-00703 – volume: 494 start-page: 138 year: 2019 ident: 4903_CR43 publication-title: Clinica chimica acta international journal of clinical chemistry doi: 10.1016/j.cca.2019.03.1617 – volume: 11 start-page: 135 issue: 2 year: 1963 ident: 4903_CR5 publication-title: Henry Ford Hosp Med Bull – volume: 73 start-page: 703 issue: 4 year: 1993 ident: 4903_CR7 publication-title: Cell doi: 10.1016/0092-8674(93)90250-t – volume: 99 start-page: 922 issue: 5 year: 2014 ident: 4903_CR19 publication-title: Haematologica doi: 10.3324/haematol.2013.093161 – volume: 293 start-page: 1653 issue: 13 year: 2005 ident: 4903_CR20 publication-title: JAMA doi: 10.1001/jama.293.13.1653 – volume: 33 start-page: 25 issue: 1 year: 2000 ident: 4903_CR10 publication-title: Crit Rev Oncol Hematol doi: 10.1016/s1040-8428(99)00052-9 – volume: 106 start-page: 3699 issue: 12 year: 2005 ident: 4903_CR16 publication-title: Blood doi: 10.1182/blood-2005-04-1717 – volume: 135 start-page: 884 issue: 12 year: 2020 ident: 4903_CR31 publication-title: Blood doi: 10.1182/blood.2020004959 – volume: 47 start-page: 881 issue: 9 year: 2000 ident: 4903_CR44 publication-title: Canadian journal of anaesthesia Journal canadien d'anesthesie doi: 10.1007/bf03019668 – volume: 11 start-page: 785 issue: 9 year: 2010 ident: 4903_CR12 publication-title: Nat Immunol doi: 10.1038/ni.1923 – volume: 2 start-page: 205 issue: 2 year: 2008 ident: 4903_CR17 publication-title: Biologics : targets & therapy doi: 10.2147/btt.s1420 – volume: 130 start-page: 3471 issue: Supplement 1 year: 2017 ident: 4903_CR23 publication-title: Blood doi: 10.1182/blood.V130.Suppl_1.3471.3471 – volume: 94 start-page: 528 issue: 2 year: 2002 ident: 4903_CR34 publication-title: Cancer doi: 10.1002/cncr.10245 – volume: 96 start-page: 92 issue: 1 year: 1997 ident: 4903_CR2 publication-title: Br J Haematol doi: 10.1046/j.1365-2141.1997.d01-1984.x – volume: 112 start-page: 3099 issue: 8 year: 2008 ident: 4903_CR38 publication-title: Blood doi: 10.1182/blood-2008-01-133918
SSID	ssj0012842
Score	2.4917772
Snippet	Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematologic disorder characterized by complement-mediated hemolysis. C5 inhibitors...
SourceID	pubmedcentral proquest pubmed crossref springer
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	1971
SubjectTerms	Adult Anemia Biomarkers Blood diseases Bone marrow Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Complement Inactivating Agents - adverse effects Dehydrogenases Drug dosages FDA approval Hematology Hemoglobin Hemoglobins Hemoglobinuria, Paroxysmal - drug therapy Hemolysis Hospitals Humans Medicine Medicine & Public Health Monoclonal antibodies Oncology Original Original Article Peptides, Cyclic - adverse effects Pharmaceuticals Quality of life
SummonAdditionalLinks	– databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zj9MwEB6hBSFeuI8sCzISbxAp8ZHjEa1YwQMrxKV9ixwfNFLXrZoU7c_fGTcJKgtI0LcqYzdxxp5v-o0_A7wsOGmCVzZtMVynslJtqq3k-NXnhF9VZn08bKI8Pa3OzuqP46awfqp2nyjJuFLPm92ySDdS9TmxVSJF5Hgdw11F0_HT528zd4ALbuQOalGnCj_jVpnf97Efjq5gzKulkr_wpTEMndz5vwe4C7dH2Mne7PzkHlxz4T7c_DAS6w_g4n1YdG0s32Irz44Foz9o2dp9N27ARXO91IFhZr5dDj3rAgsEdZfjHk5qsXDnq6huws6p4GcTrdaaimR6tMQGxFXQPZAlyZB0YYvO_xC-nrz9cvwuHQ9lSI0s5ZB6gwmS8oXUZSWl9ZWstS2NsAojvy6UajnPrRdO-9wIBI-KRNlElllRkz6beAQHYRXcE2B1pjk33NQl4kZMDFtjHTfO-pyOIlUygXx6N40ZFcvp4IxlM2stxyFtcEibOKTNRQKv5jbrnV7HX62PplfejHO3b3hJMBhTvSqBF_NlnHVEpejgVlu0KRDWEZjlCTzeecj8c0JVBSbBWQLlnu_MBqTovX8ldIuo7I2dYv6Hfb6ePOjnbf35KQ7_zfwp3OLRCalQ7ggOhs3WPYMb5sfQ9ZvncS5dAiwYGuc priority: 102 providerName: Springer Nature
Title	Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria
URI	https://link.springer.com/article/10.1007/s00277-022-04903-x https://www.ncbi.nlm.nih.gov/pubmed/35869170 https://www.proquest.com/docview/2701610868 https://www.proquest.com/docview/2693774162 https://pubmed.ncbi.nlm.nih.gov/PMC9375762
Volume	101
WOSCitedRecordID	wos000828925100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1432-0584 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0012842 issn: 0939-5555 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwELbYLkJceD8Cy8pI3CAi8SOPE4LVruBAtSqw6i1KbIdG6jqhSVF_PjOum1VZsRd6iBRlnMaasf2NZ_wNIW8ShpzgmQ4rWK5DkckqLLVgcFvHiF9lpGtXbCKdTrP5PD_3G269T6vczYluotatwj3y9yxFcAIAPPvQ_QqxahRGV30JjQNyiExlYkIOP51Oz2djHAEmXxdHyHkeSvj5YzPu8FzkwpeYzY7RLx5u9pema3jzetrkX7FTtySd3f_fzjwg9zwYpR-31vOQ3DL2Ebnz1YfbH5PNF7toKpfURduannCK27a0Mz-VGWAq7ZalpeCvr5dDTxtLLQLgpT_ZiS0W5rJ1nCf0EtOAVk6qKzF1pgdJaIARDPwGlERyksauYUg8IT_OTr-ffA59qYZQiVQMYa3AbZJ1Iso0E0LXmchLnSquJeCBMpGyYizWNTdlHSsOkFIiVRuPIs1zZG3jT8nEttY8JzSPSsYUU3kKaBLcxUppw5TRdYwFSqUISLzTUqE8jzmW01gWIwOz02wBmi2cZotNQN6Obboti8eN0kc7rRV-RPfFlcoC8np8DGMRAyylNe0aZBIAewhxWUCebW1l_DsuswRc4ygg6Z4VjQLI873_xDYLx_cNLwWvEN75bmdvV5_17168uLkXL8ld5mwf0-WOyGRYrc0rclv9Hpp-dUwO0tkFXuepu2bHfmTB3ezbxR8nkSld
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgoAL70eggJHgBBGJHedxQAgVqq7arhAqqLc0sR12pW0SNllY_hS_kRlvkmqp6K0H9rbK2BtnP48_Z8bfALwIOWmCx9rNcbl2g1jmbqYDjl8Ln_ir9HRhi01E43F8dJR82oDf_VkYSqvsfaJ11LpS9I78DY-InCABj9_V312qGkXR1b6ExgoWe-bXT9yyNW9HH_D_fcn5zsfD7V23qyrgqiAKWrdQyPBlEQZZFAeBLuIgyXSkhJa4dGWhlDnnvi6EyQpfCWQ_klTFhOdpkZDAmMB-L8Fl9OM-pZBFn78OUQt09TZqkYjElfjpDunYo3qeDZZS7jzF2oS7XF8Iz7Dbs0maf0Vq7QK4c_N_e3S34EZHtdn71dy4DRumvANXD7pkgruwHJWTaW5T1lhVsG3B6KU0q803ZVpcKOpZVrK5aRaztmHTkpVE72fduVVqMTEnlVV0YSeU5DS3VnVGiUENWmIDis_QPZAlSa9MywVO-Hvw5ULGfR82y6o0D4ElXsa54iqJkCvjZjhX2nBldOFT-VUZOOD3qEhVp9JOxUJm6aAvbZGUIpJSi6R06cCroU290ig513qrR0na-asmPYWIA8-Hy-hpKHyUlaZaoE2IVJYIPHfgwQqbw88JGYe48fcciNZQOxiQivn6lXI6sWrm2CnuebHP1z2-T2_r36N4dP4onsG13cOD_XR_NN57DNe5nXeUGLgFm-18YZ7AFfWjnTbzp3YGMzi-aNz_AdwFffM
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Nb9NAEB2VFFW98A01FFgkOIFVe-31xwEhaBsRFaIIgdSbsXfXxFJqh9iB8Nf4dcxsbFehorceyC3y7MbrvJ1965l9A_A84KQJHik7w-Xa9iOR2anyOX7NXeKvwlG5KTYRjsfR6Wk82YLf3VkYSqvsfKJx1KqS9I78gIdETpCARwd5mxYxORq-mX-3qYIURVq7chpriJzoXz9x-1a_Hh3hf_2C8-Hx58P3dlthwJZ-6Dd2LpHtizzw0zDyfZVHfpyqUHpK4DKWBkJknLsq93Sau9JDJiRIYcxzHOXFJDbmYb_XYDtEkiEGsP3ueDz51Mcw0PGbGEbsxbbAT3tkxxzcc0zolDLpKfLm2avNZfEC172YsvlX3NYsh8Ob__ODvAU3WhLO3q5nzW3Y0uUd2PnYphnchdWonBaZSWZjVc4OPUavq9lcf5O6wSVkPktLttD1ctbUrChZScR_1p5opRZTfVYZrRd2RulPC2M1TyllqEZLbECRG7oHsiRRlqJcoiu4B1-uZNz3YVBWpd4DFjsp55LLOEQWjdvkTCrNpVa5S4VZhW-B2yEkka1-O5URmSW98rRBVYKoSgyqkpUFL_s287V6yaXW-x1iktaT1ck5XCx41l9GH0SBpbTU1RJtAiS5RO25BQ_WOO1_zhNRELuhY0G4geDegPTNN6-UxdTonGOnuBvGPl91WD-_rX-P4uHlo3gKOwj35MNofPIIdrmZgpQxuA-DZrHUj-G6_NEU9eJJO50ZfL1q4P8Bys6H5w
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inhibition+of+C3+with+pegcetacoplan+results+in+normalization+of+hemolysis+markers+in+paroxysmal+nocturnal+hemoglobinuria&rft.jtitle=Annals+of+hematology&rft.au=Wong%2C+Raymond+S+M&rft.au=Pullon%2C+Humphrey+W+H&rft.au=Amine%2C+Ismail&rft.au=Bogdanovic%2C+Andrija&rft.date=2022-09-01&rft.eissn=1432-0584&rft.volume=101&rft.issue=9&rft.spage=1971&rft_id=info:doi/10.1007%2Fs00277-022-04903-x&rft_id=info%3Apmid%2F35869170&rft.externalDocID=35869170
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0939-5555&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0939-5555&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0939-5555&client=summon